Skip to main content
Divisions
Molecular diagnostics and distributed qPCR solutions.
Complete PCR solutions for molecular diagnostics.
Customised NGS for next-generation molecular insights.
Technologies
Instruments
Miniaturised qPCR devices with superior performance
Software Solutions
Cloud-based platform driven by artificial intelligence for advanced operations
Reagents
Deep multiplexing solutions and innovative reagents for all use cases
About us
Vision & Values
Our identity and the principles that guide the Group.
Numbers and Certifications
Reliability, performance and standards that define our work.
Leadership
The management team leading Helyx Industries.
About Helyx
The history, evolution and culture of our Group.
Insights
See all Insights
29 June 2026 | Market and Industry Trends
Emerging opportunities for multiplex PCR diagnostics
Multiplex PCR diagnostics creates value when it translates defined molecular targets into rapid, evidence-based decisions. The article analyses the most promising opportunities across the clinical, industrial quality, agri-food, environmental biosurveillance, AI and data governance sectors, linking them to Helyx Industries’ ‘One Group – Three Divisions’ architecture.
22 June 2026 | Distributed Diagnostics
A regional network for distributed diagnostics: a replicable model
A regional network of distributed diagnostic facilities can bring qPCR closer to the point of care without replacing the central laboratory. The article analyses the hub-and-spoke architecture, interoperability, KPIs and the role of Hyris and Vytro in the Helyx Industries S.p.A. model.
News
Press releases
10 July 2026
Global Corporate Finance LLC sottoscrive la seconda tranche di aumento di capitale in esecuzione dell’accordo di investimento sottoscritto in data 31 luglio 2025
Press releases
30 June 2026
"Warrant Helyx Industries S.p.A. 2021-2026": risultati del nono periodo di esercizio
Updates and announcements
24 June 2026
Helyx Industries in the public hospital channel: two awards in oncohematology
Updates and announcements
08 June 2026
Subsidiary Hyris awarded a public tender in Spain for the supply of SARS-CoV-2 cellular-immunity kits within a public research project
Investors
Helyx Industries is an industrial group active in the field of genetics. It has proprietary technologies and processes for complete and integrated solutions in molecular biology, from PCR to NGS. Through its divisions, it offers its solutions directly to diagnostic laboratories and hospitals or provides its services to diagnostic and industrial partners. Helyx Industries is listed on Euronext Growth in Milan.
Read more
Contact us
IT
EN
IT
EN
Divisions
Molecular diagnostics and distributed qPCR solutions.
Hyris System™
Agrifood & Nutraceuticals Catalogue
Development and OEM services
Complete PCR solutions for molecular diagnostics.
Human Health Catalogue
Customised NGS for next-generation molecular insights.
Customised NGS panels
Compatible areas & technologies
Technologies
Instruments
Miniaturised qPCR devices with superior performance
bCUBE™
bGATE™
Software Solutions
Cloud-based platform driven by artificial intelligence for advanced operations
bAPP™
Reagents
Deep multiplexing solutions and innovative reagents for all use cases
Sagitta™
Stable multiplex reagents
About Us
Vision & Values
Our identity and the principles that guide the Group.
Vision
Mission
Numbers and Certifications
Reliability, performance and standards that define our work.
Facts and Figures
Certifications
Leadership
The management team leading Helyx Industries.
People
About Helyx
The history, evolution and culture of our Group.
Our History
Timeline
Insights
News
Updates & announcements
Commercial news announced by Helyx Industries.
Read all
Press releases
Regulated and price-sensitive press releases.
Read all
Scientific Publications
Research, studies and published scientific papers.
Read all
Investors
Helyx Industries
Helyx Industries is an integrated biotech group with proprietary technologies that develops diagnostic solutions, focusing on public health, distributed diagnostics and molecular innovation.
Download Pitch Deck
Overview
Corporate Governance
Information for shareholders
Financial data
Press releases
Financial calendar
Shareholders' meeting
Analyst Coverage
Warrant
Internal dealing
Investment Agreement with GCF
Concluded extraordinary transactions
IPO
Investor Relations Contacts
Contacts
10 July, 2026
Press releases
Global Corporate Finance LLC sottoscrive la seconda tranche di aumento di capitale in esecuzione dell’accordo di investimento sottoscritto in data 31 luglio 2025
Link
24 June 2026
Helyx Industries in the public hospital channel: two awards in oncohematology
CONTINUE TO READING
08 June 2026
Subsidiary Hyris awarded a public tender in Spain for the supply of SARS-CoV-2 cellular-immunity kits within a public research project
CONTINUE TO READING
18 May 2026
Helyx Industries granted U.S. patent for its proprietary deep multiplexing technology
CONTINUE TO READING
11 May 2026
Helyx Industries Files International Patent Application for a Smart Remote Calibration Device for HYRIS bCUBE™
CONTINUE TO READING
15 April 2026
Cervical Cancer Prevention: Helyx Industries among the validated partners in the new 2026 GISCi Manual
CONTINUE TO READING
23 March 2026
Helyx Automation Accelerates: First Order Received for the New Proprietary Liquid Handling System
CONTINUE TO READING
11 February 2026
Helyx Industries enters the Next Generation Sequencing (NGS) market and joins Neonatal Screening project in Puglia
CONTINUE TO READING
19 January 2026
Helyx Industries is born: a rebranding that consolidates a new three-division industrial structure
CONTINUE TO READING
07 August 2025
Papillomavirus Screening: Self-sampling with HPV-Selfy is Effective and Well-Accepted by Women, a New Study Confirms.
CONTINUE TO READING
06 August 2025
COMMUNICATION OF CONCESSION FOR POR FESR 2021-2027
CONTINUE TO READING
24 June 2026
Helyx Industries in the public hospital channel: two awards in oncohematology
CONTINUE TO READING
08 June 2026
Subsidiary Hyris awarded a public tender in Spain for the supply of SARS-CoV-2 cellular-immunity kits within a public research project
CONTINUE TO READING
18 May 2026
Helyx Industries granted U.S. patent for its proprietary deep multiplexing technology
CONTINUE TO READING
11 May 2026
Helyx Industries Files International Patent Application for a Smart Remote Calibration Device for HYRIS bCUBE™
CONTINUE TO READING
15 April 2026
Cervical Cancer Prevention: Helyx Industries among the validated partners in the new 2026 GISCi Manual
CONTINUE TO READING
23 March 2026
Helyx Automation Accelerates: First Order Received for the New Proprietary Liquid Handling System
CONTINUE TO READING
11 February 2026
Helyx Industries enters the Next Generation Sequencing (NGS) market and joins Neonatal Screening project in Puglia
CONTINUE TO READING
19 January 2026
Helyx Industries is born: a rebranding that consolidates a new three-division industrial structure
CONTINUE TO READING
07 August 2025
Papillomavirus Screening: Self-sampling with HPV-Selfy is Effective and Well-Accepted by Women, a New Study Confirms.
CONTINUE TO READING
06 August 2025
COMMUNICATION OF CONCESSION FOR POR FESR 2021-2027
CONTINUE TO READING
